Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Class III Device Recalls An Afterthought? Not So Fast . . .

This article was originally published in The Silver Sheet

Executive Summary

Low-risk class III medical device recalls sometimes fade into the background because they comprise only a sliver of the overall corrections and removals in a given year. Nevertheless, manufacturers should be aware that any decisions they make regarding class III actions are still going to receive FDA attention. One example: “The justification for not reporting a recall is an area that the agency frequently takes a very close look at,” CDRH Recall Branch Chief Ron Brown says. When FDA wrote its recalls regulation it left the decision about whether to report class III events up to manufacturers. Reporting such low-risk recalls is not required by the agency, but is obviously encouraged if firms discover that the risk to device users is somewhat significant. Such a gray area can leave firms wondering about when it’s necessary to report class III’s – or even whether they should be reported in the first place.

You may also be interested in...

QUOTED. 20 February 2020. Steven Raman.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.

Novartis Logs Into India With Digital Innovation Hub

Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.

Rx List Price Inflation Penalty Endorsed By US HHS Secretary

Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts